Literature DB >> 24667960

Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition.

Stanley R Riddell1, Daniel Sommermeyer, Carolina Berger, Lingfeng Steven Liu, Ashwini Balakrishnan, Alex Salter, Michael Hudecek, David G Maloney, Cameron J Turtle.   

Abstract

The ability to engineer T cells to recognize tumor cells through genetic modification with a synthetic chimeric antigen receptor has ushered in a new era in cancer immunotherapy. The most advanced clinical applications are in targeting CD19 on B-cell malignancies. The clinical trials of CD19 chimeric antigen receptor therapy have thus far not attempted to select defined subsets before transduction or imposed uniformity of the CD4 and CD8 cell composition of the cell products. This review will discuss the rationale for and challenges to using adoptive therapy with genetically modified T cells of defined subset and phenotypic composition.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24667960      PMCID： PMC4149222          DOI： 10.1097/PPO.0000000000000036

Source DB:  PubMed          Journal:  Cancer J        ISSN： 1528-9117            Impact factor:   3.360


  29 in total

1.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

Authors:  James N Kochenderfer; Mark E Dudley; Steven A Feldman; Wyndham H Wilson; David E Spaner; Irina Maric; Maryalice Stetler-Stevenson; Giao Q Phan; Marybeth S Hughes; Richard M Sherry; James C Yang; Udai S Kammula; Laura Devillier; Robert Carpenter; Debbie-Ann N Nathan; Richard A Morgan; Carolyn Laurencot; Steven A Rosenberg
Journal:  Blood       Date:  2011-12-08       Impact factor: 22.113

2.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

Authors:  David L Porter; Bruce L Levine; Michael Kalos; Adam Bagg; Carl H June
Journal:  N Engl J Med       Date:  2011-08-10       Impact factor: 91.245

3.  T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.

Authors:  Michael Kalos; Bruce L Levine; David L Porter; Sharyn Katz; Stephan A Grupp; Adam Bagg; Carl H June
Journal:  Sci Transl Med       Date:  2011-08-10       Impact factor: 17.956

Review 4.  Paths to stemness: building the ultimate antitumour T cell.

Authors:  Luca Gattinoni; Christopher A Klebanoff; Nicholas P Restifo
Journal:  Nat Rev Cancer       Date:  2012-09-21       Impact factor: 60.716

5.  Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells.

Authors:  Seitaro Terakura; Tori N Yamamoto; Rebecca A Gardner; Cameron J Turtle; Michael C Jensen; Stanley R Riddell
Journal:  Blood       Date:  2011-10-26       Impact factor: 22.113

6.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

Authors:  Renier J Brentjens; Isabelle Rivière; Jae H Park; Marco L Davila; Xiuyan Wang; Jolanta Stefanski; Clare Taylor; Raymond Yeh; Shirley Bartido; Oriana Borquez-Ojeda; Malgorzata Olszewska; Yvette Bernal; Hollie Pegram; Mark Przybylowski; Daniel Hollyman; Yelena Usachenko; Domenick Pirraglia; James Hosey; Elmer Santos; Elizabeth Halton; Peter Maslak; David Scheinberg; Joseph Jurcic; Mark Heaney; Glenn Heller; Mark Frattini; Michel Sadelain
Journal:  Blood       Date:  2011-08-17       Impact factor: 22.113

7.  Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.

Authors:  Xiuli Wang; Araceli Naranjo; Christine E Brown; Cherrilyn Bautista; Chinglam W Wong; Wen-Chung Chang; Brenda Aguilar; Julie R Ostberg; Stanley R Riddell; Stephen J Forman; Michael C Jensen
Journal:  J Immunother       Date:  2012 Nov-Dec       Impact factor: 4.456

8.  CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.

Authors:  Renier J Brentjens; Marco L Davila; Isabelle Riviere; Jae Park; Xiuyan Wang; Lindsay G Cowell; Shirley Bartido; Jolanta Stefanski; Clare Taylor; Malgorzata Olszewska; Oriana Borquez-Ojeda; Jinrong Qu; Teresa Wasielewska; Qing He; Yvette Bernal; Ivelise V Rijo; Cyrus Hedvat; Rachel Kobos; Kevin Curran; Peter Steinherz; Joseph Jurcic; Todd Rosenblat; Peter Maslak; Mark Frattini; Michel Sadelain
Journal:  Sci Transl Med       Date:  2013-03-20       Impact factor: 17.956

9.  Proliferation-linked apoptosis of adoptively transferred T cells after IL-15 administration in macaques.

Authors:  Carolina Berger; Michael Berger; Brian C Beard; Hans-Peter Kiem; Theodore A Gooley; Stanley R Riddell
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

10.  Novel serial positive enrichment technology enables clinical multiparameter cell sorting.

Authors:  Christian Stemberger; Stefan Dreher; Claudia Tschulik; Christine Piossek; Jeannette Bet; Tori N Yamamoto; Matthias Schiemann; Michael Neuenhahn; Klaus Martin; Martin Schlapschy; Arne Skerra; Thomas Schmidt; Matthias Edinger; Stanley R Riddell; Lothar Germeroth; Dirk H Busch
Journal:  PLoS One       Date:  2012-04-24       Impact factor: 3.240
View more
  43 in total

Review 1.  Smart CARs engineered for cancer immunotherapy.

Authors:  Saul J Priceman; Stephen J Forman; Christine E Brown
Journal:  Curr Opin Oncol       Date:  2015-11       Impact factor: 3.645

Review 2.  Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies.

Authors:  X Wang; I Rivière
Journal:  Cancer Gene Ther       Date:  2015-02-27       Impact factor: 5.987

Review 3.  Prospects of chimeric antigen receptor T cell therapy in ovarian cancer.

Authors:  Vishal Jindal; Ena Arora; Sorab Gupta; Amos Lal; Muhammad Masab; Rashmika Potdar
Journal:  Med Oncol       Date:  2018-04-12       Impact factor: 3.064

Review 4.  New cell sources for T cell engineering and adoptive immunotherapy.

Authors:  Maria Themeli; Isabelle Rivière; Michel Sadelain
Journal:  Cell Stem Cell       Date:  2015-04-02       Impact factor: 24.633

5.  Equal opportunity CAR T cells.

Authors:  Rayne H Rouce; Helen E Heslop
Journal:  Blood       Date:  2017-06-22       Impact factor: 22.113

6.  Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.

Authors:  David T Rodgers; Magdalena Mazagova; Eric N Hampton; Yu Cao; Nitya S Ramadoss; Ian R Hardy; Andrew Schulman; Juanjuan Du; Feng Wang; Oded Singer; Jennifer Ma; Vanessa Nunez; Jiayin Shen; Ashley K Woods; Timothy M Wright; Peter G Schultz; Chan Hyuk Kim; Travis S Young
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-12       Impact factor: 11.205

7.  Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy.

Authors:  Christopher A Klebanoff; Joseph G Crompton; Anthony J Leonardi; Tori N Yamamoto; Smita S Chandran; Robert L Eil; Madhusudhanan Sukumar; Suman K Vodnala; Jinhui Hu; Yun Ji; David Clever; Mary A Black; Devikala Gurusamy; Michael J Kruhlak; Ping Jin; David F Stroncek; Luca Gattinoni; Steven A Feldman; Nicholas P Restifo
Journal:  JCI Insight       Date:  2017-12-07

Review 8.  Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice.

Authors:  Vishal Jindal; Ena Arora; Muhammad Masab; Sorab Gupta
Journal:  Med Oncol       Date:  2018-05-04       Impact factor: 3.064

9.  Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors.

Authors:  R Monjezi; C Miskey; T Gogishvili; M Schleef; M Schmeer; H Einsele; Z Ivics; M Hudecek
Journal:  Leukemia       Date:  2016-06-24       Impact factor: 11.528

Review 10.  CAR therapy: the CD19 paradigm.

Authors:  Michel Sadelain
Journal:  J Clin Invest       Date:  2015-09-01       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.